![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Health Canada Approves Alecensaro for Aggressive Lung Cancer
Health Canada Approves Alecensaro for Aggressive Lung Cancer
Health Canada has approved Alecensaro as a monotherapy for the treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
The approval of Alecensaro is based on two pivotal Phase I/II studies, in which the treatment shrank tumors in up to 50 percent of people with ALK-positive NSCLC whose disease had worsened on crizotinib.
Alecensaro is a twice-daily oral medicine that blocks the activity of the ALK protein, which may slow down the growth and spread of NSCLC.
Upcoming Events
-
21Oct